id	sid	tid	token	lemma	pos
dpc-4713	1	1	dermatology	dermatology	NOUN
dpc-4713	1	2	:	:	PUNCT
dpc-4713	1	3	practical	practical	ADJ
dpc-4713	1	4	and	and	CCONJ
dpc-4713	1	5	conceptual	conceptual	ADJ
dpc-4713	1	6	research	research	NOUN
dpc-4713	1	7	letter	letter	NOUN
dpc-4713	2	1	|	|	ADV
dpc-4713	2	2	dermatol	dermatol	ADJ
dpc-4713	2	3	pract	pract	NOUN
dpc-4713	2	4	concept	concept	NOUN
dpc-4713	2	5	.	.	PUNCT
dpc-4713	3	1	2025;15(1):4713	2025;15(1):4713	NUM
dpc-4713	3	2	1	1	NUM
dpc-4713	3	3	significance	significance	NOUN
dpc-4713	3	4	of	of	ADP
dpc-4713	3	5	clinical	clinical	ADJ
dpc-4713	3	6	-	-	PUNCT
dpc-4713	3	7	pathological	pathological	ADJ
dpc-4713	3	8	correlation	correlation	NOUN
dpc-4713	3	9	in	in	ADP
dpc-4713	3	10	ponatinib	ponatinib	NOUN
dpc-4713	3	11	reactions	reaction	NOUN
dpc-4713	3	12	judith	judith	PROPN
dpc-4713	3	13	monserrat	monserrat	PROPN
dpc-4713	3	14	corona	corona	PROPN
dpc-4713	3	15	-	-	PUNCT
dpc-4713	3	16	herrera1	herrera1	PROPN
dpc-4713	3	17	,	,	PUNCT
dpc-4713	3	18	fanny	fanny	PROPN
dpc-4713	3	19	carolina	carolina	PROPN
dpc-4713	3	20	lopez	lopez	PROPN
dpc-4713	3	21	-	-	PUNCT
dpc-4713	3	22	jimenez1	jimenez1	PROPN
dpc-4713	3	23	,	,	PUNCT
dpc-4713	3	24	verónica	verónica	PROPN
dpc-4713	3	25	monserrat	monserrat	PROPN
dpc-4713	3	26	díaz	díaz	PROPN
dpc-4713	3	27	sánchez1	sánchez1	PROPN
dpc-4713	3	28	,	,	PUNCT
dpc-4713	3	29	betzabé	betzabé	ADJ
dpc-4713	3	30	quiles	quile	NOUN
dpc-4713	3	31	-	-	PUNCT
dpc-4713	3	32	martínez1	martínez1	NOUN
dpc-4713	3	33	,	,	PUNCT
dpc-4713	3	34	marcela	marcela	PROPN
dpc-4713	3	35	saeb	saeb	PROPN
dpc-4713	3	36	-	-	PUNCT
dpc-4713	3	37	lima2	lima2	PROPN
dpc-4713	3	38	,	,	PUNCT
dpc-4713	3	39	silvia	silvia	PROPN
dpc-4713	3	40	méndez	méndez	PROPN
dpc-4713	3	41	-	-	PUNCT
dpc-4713	3	42	flores1	flores1	NOUN
dpc-4713	3	43	1	1	NUM
dpc-4713	3	44	dermatology	dermatology	NOUN
dpc-4713	3	45	department	department	NOUN
dpc-4713	3	46	,	,	PUNCT
dpc-4713	3	47	national	national	PROPN
dpc-4713	3	48	institute	institute	PROPN
dpc-4713	3	49	of	of	ADP
dpc-4713	3	50	nutrition	nutrition	PROPN
dpc-4713	3	51	salvador	salvador	PROPN
dpc-4713	3	52	zubirán	zubirán	PROPN
dpc-4713	3	53	,	,	PUNCT
dpc-4713	3	54	mexico	mexico	PROPN
dpc-4713	3	55	city	city	PROPN
dpc-4713	3	56	,	,	PUNCT
dpc-4713	3	57	mexico	mexico	PROPN
dpc-4713	3	58	2	2	NUM
dpc-4713	3	59	pathology	pathology	NOUN
dpc-4713	3	60	department	department	NOUN
dpc-4713	3	61	,	,	PUNCT
dpc-4713	3	62	national	national	PROPN
dpc-4713	3	63	institute	institute	PROPN
dpc-4713	3	64	of	of	ADP
dpc-4713	3	65	health	health	PROPN
dpc-4713	3	66	sciences	sciences	PROPN
dpc-4713	3	67	and	and	CCONJ
dpc-4713	3	68	nutrition	nutrition	NOUN
dpc-4713	3	69	salvador	salvador	PROPN
dpc-4713	3	70	zubirán	zubirán	PROPN
dpc-4713	3	71	,	,	PUNCT
dpc-4713	3	72	mexico	mexico	PROPN
dpc-4713	3	73	city	city	PROPN
dpc-4713	3	74	,	,	PUNCT
dpc-4713	3	75	méxico	méxico	PROPN
dpc-4713	3	76	key	key	ADJ
dpc-4713	3	77	words	word	NOUN
dpc-4713	3	78	:	:	PUNCT
dpc-4713	3	79	ponatinib	ponatinib	NOUN
dpc-4713	3	80	,	,	PUNCT
dpc-4713	3	81	adverse	adverse	ADJ
dpc-4713	3	82	drug	drug	NOUN
dpc-4713	3	83	reactions	reaction	NOUN
dpc-4713	3	84	,	,	PUNCT
dpc-4713	3	85	stevens	stevens	PROPN
dpc-4713	3	86	-	-	PUNCT
dpc-4713	3	87	johnson	johnson	PROPN
dpc-4713	3	88	syndrome	syndrome	PROPN
dpc-4713	3	89	citation	citation	NOUN
dpc-4713	3	90	:	:	PUNCT
dpc-4713	3	91	corona	corona	NOUN
dpc-4713	3	92	-	-	PUNCT
dpc-4713	3	93	herrera	herrera	PROPN
dpc-4713	3	94	jm	jm	PROPN
dpc-4713	3	95	,	,	PUNCT
dpc-4713	3	96	lopez	lopez	PROPN
dpc-4713	3	97	-	-	PUNCT
dpc-4713	3	98	jimenez	jimenez	PROPN
dpc-4713	3	99	fc	fc	PROPN
dpc-4713	3	100	,	,	PUNCT
dpc-4713	3	101	díaz	díaz	PROPN
dpc-4713	3	102	sánchez	sánchez	PROPN
dpc-4713	3	103	vm	vm	PROPN
dpc-4713	3	104	,	,	PUNCT
dpc-4713	3	105	quiles	quile	NOUN
dpc-4713	3	106	-	-	PUNCT
dpc-4713	3	107	martínez	martínez	PROPN
dpc-4713	3	108	b	b	NOUN
dpc-4713	3	109	,	,	PUNCT
dpc-4713	3	110	saeb	saeb	NOUN
dpc-4713	3	111	-	-	PUNCT
dpc-4713	3	112	lima	lima	PROPN
dpc-4713	3	113	m	m	PROPN
dpc-4713	3	114	,	,	PUNCT
dpc-4713	3	115	méndez	méndez	PROPN
dpc-4713	3	116	-	-	PUNCT
dpc-4713	3	117	flores	flores	PROPN
dpc-4713	3	118	s.	s.	PROPN
dpc-4713	3	119	significance	significance	NOUN
dpc-4713	3	120	of	of	ADP
dpc-4713	3	121	 	 	SPACE
dpc-4713	3	122	clinical	clinical	ADJ
dpc-4713	3	123	-	-	PUNCT
dpc-4713	3	124	pathological	pathological	ADJ
dpc-4713	3	125	correlation	correlation	NOUN
dpc-4713	3	126	in	in	ADP
dpc-4713	3	127	ponatinib	ponatinib	NOUN
dpc-4713	3	128	reactions	reaction	NOUN
dpc-4713	3	129	.	.	PUNCT
dpc-4713	4	1	dermatol	dermatol	NOUN
dpc-4713	4	2	pract	pract	PROPN
dpc-4713	4	3	concept	concept	NOUN
dpc-4713	4	4	.	.	PUNCT
dpc-4713	5	1	2025;15(1):4713	2025;15(1):4713	X
dpc-4713	5	2	.	.	PUNCT
dpc-4713	6	1	doi	doi	NOUN
dpc-4713	6	2	:	:	PUNCT
dpc-4713	6	3	https://doi.org/10.5826	https://doi.org/10.5826	PROPN
dpc-4713	6	4	/dpc.1501a4713	/dpc.1501a4713	PUNCT
dpc-4713	6	5	accepted	accept	VERB
dpc-4713	6	6	:	:	PUNCT
dpc-4713	6	7	august	august	PROPN
dpc-4713	6	8	1	1	NUM
dpc-4713	6	9	,	,	PUNCT
dpc-4713	6	10	2024	2024	NUM
dpc-4713	6	11	;	;	PUNCT
dpc-4713	6	12	published	publish	VERB
dpc-4713	6	13	:	:	PUNCT
dpc-4713	7	1	january	january	PROPN
dpc-4713	7	2	2025	2025	NUM
dpc-4713	7	3	copyright	copyright	NOUN
dpc-4713	7	4	:	:	PUNCT
dpc-4713	7	5	©	©	PROPN
dpc-4713	7	6	2024	2024	NUM
dpc-4713	7	7	corona	corona	PROPN
dpc-4713	7	8	-	-	PUNCT
dpc-4713	7	9	herrera	herrera	NOUN
dpc-4713	7	10	et	et	PROPN
dpc-4713	7	11	al	al	PROPN
dpc-4713	7	12	.	.	PUNCT
dpc-4713	8	1	this	this	PRON
dpc-4713	8	2	is	be	AUX
dpc-4713	8	3	an	an	DET
dpc-4713	8	4	open	open	ADJ
dpc-4713	8	5	-	-	PUNCT
dpc-4713	8	6	access	access	NOUN
dpc-4713	8	7	article	article	NOUN
dpc-4713	8	8	distributed	distribute	VERB
dpc-4713	8	9	under	under	ADP
dpc-4713	8	10	the	the	DET
dpc-4713	8	11	terms	term	NOUN
dpc-4713	8	12	of	of	ADP
dpc-4713	8	13	the	the	DET
dpc-4713	8	14	creative	creative	ADJ
dpc-4713	8	15	commons	common	NOUN
dpc-4713	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4713	8	17	license	license	NOUN
dpc-4713	8	18	(	(	PUNCT
dpc-4713	8	19	by	by	ADP
dpc-4713	8	20	-	-	PUNCT
dpc-4713	8	21	nc-4.0	nc-4.0	NOUN
dpc-4713	8	22	)	)	PUNCT
dpc-4713	8	23	,	,	PUNCT
dpc-4713	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4713	8	25	,	,	PUNCT
dpc-4713	8	26	which	which	PRON
dpc-4713	8	27	permits	permit	VERB
dpc-4713	8	28	unrestricted	unrestricted	ADJ
dpc-4713	8	29	noncommercial	noncommercial	ADJ
dpc-4713	8	30	use	use	NOUN
dpc-4713	8	31	,	,	PUNCT
dpc-4713	8	32	distribution	distribution	NOUN
dpc-4713	8	33	,	,	PUNCT
dpc-4713	8	34	and	and	CCONJ
dpc-4713	8	35	reproduction	reproduction	NOUN
dpc-4713	8	36	in	in	ADP
dpc-4713	8	37	any	any	DET
dpc-4713	8	38	medium	medium	NOUN
dpc-4713	8	39	,	,	PUNCT
dpc-4713	8	40	provided	provide	VERB
dpc-4713	8	41	the	the	DET
dpc-4713	8	42	original	original	ADJ
dpc-4713	8	43	authors	author	NOUN
dpc-4713	8	44	and	and	CCONJ
dpc-4713	8	45	source	source	NOUN
dpc-4713	8	46	are	be	AUX
dpc-4713	8	47	credited	credit	VERB
dpc-4713	8	48	.	.	PUNCT
dpc-4713	9	1	funding	funding	NOUN
dpc-4713	9	2	:	:	PUNCT
dpc-4713	9	3	none	none	NOUN
dpc-4713	9	4	.	.	PUNCT
dpc-4713	10	1	competing	compete	VERB
dpc-4713	10	2	interests	interest	NOUN
dpc-4713	10	3	:	:	PUNCT
dpc-4713	10	4	none	none	NOUN
dpc-4713	10	5	.	.	PUNCT
dpc-4713	11	1	authorship	authorship	NOUN
dpc-4713	11	2	:	:	PUNCT
dpc-4713	11	3	all	all	DET
dpc-4713	11	4	authors	author	NOUN
dpc-4713	11	5	have	have	AUX
dpc-4713	11	6	contributed	contribute	VERB
dpc-4713	11	7	significantly	significantly	ADV
dpc-4713	11	8	to	to	ADP
dpc-4713	11	9	this	this	DET
dpc-4713	11	10	publication	publication	NOUN
dpc-4713	11	11	.	.	PUNCT
dpc-4713	12	1	corresponding	correspond	VERB
dpc-4713	12	2	author	author	NOUN
dpc-4713	12	3	:	:	PUNCT
dpc-4713	12	4	silvia	silvia	PROPN
dpc-4713	12	5	méndez	méndez	PROPN
dpc-4713	12	6	-	-	PUNCT
dpc-4713	12	7	flores	flores	PROPN
dpc-4713	12	8	md	md	PROPN
dpc-4713	12	9	,	,	PUNCT
dpc-4713	12	10	phd	phd	NOUN
dpc-4713	12	11	,	,	PUNCT
dpc-4713	12	12	dermatology	dermatology	NOUN
dpc-4713	12	13	department	department	NOUN
dpc-4713	12	14	,	,	PUNCT
dpc-4713	12	15	national	national	PROPN
dpc-4713	12	16	institute	institute	PROPN
dpc-4713	12	17	of	of	ADP
dpc-4713	12	18	nutrition	nutrition	PROPN
dpc-4713	12	19	salvador	salvador	PROPN
dpc-4713	12	20	zubirán	zubirán	PROPN
dpc-4713	12	21	.	.	PUNCT
dpc-4713	13	1	vasco	vasco	PROPN
dpc-4713	13	2	de	de	PROPN
dpc-4713	13	3	quiroga	quiroga	PROPN
dpc-4713	13	4	15	15	NUM
dpc-4713	13	5	,	,	PUNCT
dpc-4713	13	6	tlalpan	tlalpan	NOUN
dpc-4713	13	7	,	,	PUNCT
dpc-4713	13	8	14080	14080	NUM
dpc-4713	13	9	,	,	PUNCT
dpc-4713	13	10	mexico	mexico	PROPN
dpc-4713	13	11	city	city	PROPN
dpc-4713	13	12	,	,	PUNCT
dpc-4713	13	13	mexico	mexico	PROPN
dpc-4713	13	14	.	.	PUNCT
dpc-4713	14	1	e	e	X
dpc-4713	14	2	-	-	NOUN
dpc-4713	14	3	mail	mail	NOUN
dpc-4713	14	4	:	:	PUNCT
dpc-4713	14	5	silvia.mendezf@incmnsz.mx	silvia.mendezf@incmnsz.mx	NOUN
dpc-4713	14	6	introduction	introduction	NOUN
dpc-4713	14	7	the	the	DET
dpc-4713	14	8	advent	advent	NOUN
dpc-4713	14	9	of	of	ADP
dpc-4713	14	10	molecular	molecular	ADJ
dpc-4713	14	11	therapies	therapy	NOUN
dpc-4713	14	12	targeting	target	VERB
dpc-4713	14	13	specific	specific	ADJ
dpc-4713	14	14	cellular	cellular	ADJ
dpc-4713	14	15	pathways	pathway	NOUN
dpc-4713	14	16	has	have	AUX
dpc-4713	14	17	significantly	significantly	ADV
dpc-4713	14	18	enhanced	enhance	VERB
dpc-4713	14	19	the	the	DET
dpc-4713	14	20	prognosis	prognosis	NOUN
dpc-4713	14	21	for	for	ADP
dpc-4713	14	22	numerous	numerous	ADJ
dpc-4713	14	23	cancer	cancer	NOUN
dpc-4713	14	24	patients	patient	NOUN
dpc-4713	14	25	.	.	PUNCT
dpc-4713	15	1	however	however	ADV
dpc-4713	15	2	,	,	PUNCT
dpc-4713	15	3	these	these	DET
dpc-4713	15	4	advancements	advancement	NOUN
dpc-4713	15	5	often	often	ADV
dpc-4713	15	6	come	come	VERB
dpc-4713	15	7	with	with	ADP
dpc-4713	15	8	diverse	diverse	ADJ
dpc-4713	15	9	cutaneous	cutaneous	ADJ
dpc-4713	15	10	adverse	adverse	ADJ
dpc-4713	15	11	drug	drug	NOUN
dpc-4713	15	12	reactions	reaction	NOUN
dpc-4713	15	13	(	(	PUNCT
dpc-4713	15	14	cadr	cadr	PROPN
dpc-4713	15	15	)	)	PUNCT
dpc-4713	15	16	.	.	PUNCT
dpc-4713	16	1	these	these	DET
dpc-4713	16	2	reactions	reaction	NOUN
dpc-4713	16	3	can	can	AUX
dpc-4713	16	4	be	be	AUX
dpc-4713	16	5	serious	serious	ADJ
dpc-4713	16	6	,	,	PUNCT
dpc-4713	16	7	such	such	ADJ
dpc-4713	16	8	as	as	ADP
dpc-4713	16	9	in	in	ADP
dpc-4713	16	10	stevens	stevens	PROPN
dpc-4713	16	11	-	-	PUNCT
dpc-4713	16	12	johnson	johnson	PROPN
dpc-4713	16	13	syndrome	syndrome	PROPN
dpc-4713	16	14	(	(	PUNCT
dpc-4713	16	15	sjs	sjs	PROPN
dpc-4713	16	16	)	)	PUNCT
dpc-4713	16	17	,	,	PUNCT
dpc-4713	16	18	which	which	PRON
dpc-4713	16	19	has	have	AUX
dpc-4713	16	20	been	be	AUX
dpc-4713	16	21	reported	report	VERB
dpc-4713	16	22	as	as	ADP
dpc-4713	16	23	an	an	DET
dpc-4713	16	24	adverse	adverse	ADJ
dpc-4713	16	25	reaction	reaction	NOUN
dpc-4713	16	26	induced	induce	VERB
dpc-4713	16	27	by	by	ADP
dpc-4713	16	28	tyrosine	tyrosine	PROPN
dpc-4713	16	29	kinase	kinase	PROPN
dpc-4713	16	30	inhibitors	inhibitor	NOUN
dpc-4713	16	31	(	(	PUNCT
dpc-4713	16	32	tkis	tkis	NOUN
dpc-4713	16	33	)	)	PUNCT
dpc-4713	16	34	like	like	ADP
dpc-4713	16	35	imatinib	imatinib	NOUN
dpc-4713	16	36	and	and	CCONJ
dpc-4713	16	37	masitinib	masitinib	NOUN
dpc-4713	16	38	.	.	PUNCT
dpc-4713	17	1	there	there	PRON
dpc-4713	17	2	have	have	AUX
dpc-4713	17	3	been	be	AUX
dpc-4713	17	4	no	no	DET
dpc-4713	17	5	reports	report	NOUN
dpc-4713	17	6	of	of	ADP
dpc-4713	17	7	sjs	sjs	PROPN
dpc-4713	17	8	induced	induce	VERB
dpc-4713	17	9	by	by	ADP
dpc-4713	17	10	ponatinib	ponatinib	NOUN
dpc-4713	17	11	[	[	X
dpc-4713	17	12	1	1	NUM
dpc-4713	17	13	]	]	PUNCT
dpc-4713	17	14	.	.	PUNCT
dpc-4713	18	1	ponatinib	ponatinib	NOUN
dpc-4713	18	2	is	be	AUX
dpc-4713	18	3	a	a	DET
dpc-4713	18	4	third	third	ADJ
dpc-4713	18	5	-	-	PUNCT
dpc-4713	18	6	generation	generation	NOUN
dpc-4713	18	7	tki	tki	NOUN
dpc-4713	18	8	specifically	specifically	ADV
dpc-4713	18	9	developed	develop	VERB
dpc-4713	18	10	to	to	PART
dpc-4713	18	11	target	target	VERB
dpc-4713	18	12	the	the	DET
dpc-4713	18	13	gatekeeper	gatekeeper	NOUN
dpc-4713	18	14	t315i	t315i	PROPN
dpc-4713	18	15	mutation	mutation	NOUN
dpc-4713	18	16	.	.	PUNCT
dpc-4713	19	1	it	it	PRON
dpc-4713	19	2	is	be	AUX
dpc-4713	19	3	currently	currently	ADV
dpc-4713	19	4	approved	approve	VERB
dpc-4713	19	5	for	for	ADP
dpc-4713	19	6	the	the	DET
dpc-4713	19	7	treatment	treatment	NOUN
dpc-4713	19	8	of	of	ADP
dpc-4713	19	9	chronic	chronic	ADJ
dpc-4713	19	10	myeloid	myeloid	NOUN
dpc-4713	19	11	leukemia	leukemia	NOUN
dpc-4713	19	12	in	in	ADP
dpc-4713	19	13	all	all	DET
dpc-4713	19	14	phases	phase	NOUN
dpc-4713	19	15	of	of	ADP
dpc-4713	19	16	the	the	DET
dpc-4713	19	17	disease	disease	NOUN
dpc-4713	19	18	,	,	PUNCT
dpc-4713	19	19	particularly	particularly	ADV
dpc-4713	19	20	for	for	ADP
dpc-4713	19	21	patients	patient	NOUN
dpc-4713	19	22	who	who	PRON
dpc-4713	19	23	have	have	AUX
dpc-4713	19	24	developed	develop	VERB
dpc-4713	19	25	resistance	resistance	NOUN
dpc-4713	19	26	to	to	ADP
dpc-4713	19	27	or	or	CCONJ
dpc-4713	19	28	can	can	AUX
dpc-4713	19	29	not	not	PART
dpc-4713	19	30	tolerate	tolerate	VERB
dpc-4713	19	31	dasatinib	dasatinib	NOUN
dpc-4713	19	32	or	or	CCONJ
dpc-4713	19	33	nilotinib	nilotinib	NOUN
dpc-4713	19	34	,	,	PUNCT
dpc-4713	19	35	and	and	CCONJ
dpc-4713	19	36	for	for	ADP
dpc-4713	19	37	those	those	PRON
dpc-4713	19	38	with	with	ADP
dpc-4713	19	39	the	the	DET
dpc-4713	19	40	t315i	t315i	PROPN
dpc-4713	19	41	mutation	mutation	NOUN
dpc-4713	19	42	for	for	ADP
dpc-4713	19	43	whom	whom	PRON
dpc-4713	19	44	imatinib	imatinib	NOUN
dpc-4713	19	45	is	be	AUX
dpc-4713	19	46	no	no	ADV
dpc-4713	19	47	longer	long	ADV
dpc-4713	19	48	effective	effective	ADJ
dpc-4713	19	49	.	.	PUNCT
dpc-4713	20	1	ponatinib	ponatinib	NOUN
dpc-4713	20	2	is	be	AUX
dpc-4713	20	3	also	also	ADV
dpc-4713	20	4	indicated	indicate	VERB
dpc-4713	20	5	for	for	ADP
dpc-4713	20	6	philadelphia	philadelphia	PROPN
dpc-4713	20	7	chromosome	chromosome	NOUN
dpc-4713	20	8	-	-	PUNCT
dpc-4713	20	9	positive	positive	ADJ
dpc-4713	20	10	acute	acute	ADJ
dpc-4713	20	11	lymphoblastic	lymphoblastic	ADJ
dpc-4713	20	12	leukemia	leukemia	NOUN
dpc-4713	20	13	(	(	PUNCT
dpc-4713	20	14	ph+	ph+	VERB
dpc-4713	20	15	all	all	PRON
dpc-4713	20	16	)	)	PUNCT
dpc-4713	21	1	[	[	X
dpc-4713	21	2	2	2	NUM
dpc-4713	21	3	]	]	PUNCT
dpc-4713	21	4	.	.	PUNCT
dpc-4713	22	1	with	with	ADP
dpc-4713	22	2	over	over	ADP
dpc-4713	22	3	10	10	NUM
dpc-4713	22	4	years	year	NOUN
dpc-4713	22	5	on	on	ADP
dpc-4713	22	6	the	the	DET
dpc-4713	22	7	market	market	NOUN
dpc-4713	22	8	,	,	PUNCT
dpc-4713	22	9	some	some	DET
dpc-4713	22	10	cadr	cadr	PROPN
dpc-4713	22	11	have	have	AUX
dpc-4713	22	12	been	be	AUX
dpc-4713	22	13	reported	report	VERB
dpc-4713	22	14	,	,	PUNCT
dpc-4713	22	15	including	include	VERB
dpc-4713	22	16	pityriasis	pityriasis	NOUN
dpc-4713	22	17	rubra	rubra	NOUN
dpc-4713	22	18	pilaris	pilaris	NOUN
dpc-4713	22	19	-	-	PUNCT
dpc-4713	22	20	like	like	ADJ
dpc-4713	22	21	eruptions	eruption	NOUN
dpc-4713	22	22	,	,	PUNCT
dpc-4713	22	23	ichthyosiform	ichthyosiform	NOUN
dpc-4713	22	24	eruptions	eruption	NOUN
dpc-4713	22	25	,	,	PUNCT
dpc-4713	22	26	and	and	CCONJ
dpc-4713	22	27	erythematous	erythematous	ADJ
dpc-4713	22	28	rash	rash	NOUN
dpc-4713	22	29	[	[	X
dpc-4713	22	30	3,4	3,4	NUM
dpc-4713	22	31	]	]	PUNCT
dpc-4713	22	32	.	.	PUNCT
dpc-4713	23	1	recently	recently	ADV
dpc-4713	23	2	,	,	PUNCT
dpc-4713	23	3	the	the	DET
dpc-4713	23	4	term	term	NOUN
dpc-4713	23	5	“	"	PUNCT
dpc-4713	23	6	ponatinib	ponatinib	ADV
dpc-4713	23	7	-	-	PUNCT
dpc-4713	23	8	induced	induce	VERB
dpc-4713	23	9	desquamation	desquamation	NOUN
dpc-4713	23	10	”	"	PUNCT
dpc-4713	23	11	described	describe	VERB
dpc-4713	23	12	sheet	sheet	NOUN
dpc-4713	23	13	-	-	PUNCT
dpc-4713	23	14	like	like	ADJ
dpc-4713	23	15	desquamation	desquamation	NOUN
dpc-4713	23	16	,	,	PUNCT
dpc-4713	23	17	symmetrical	symmetrical	ADJ
dpc-4713	23	18	dermatitis	dermatitis	NOUN
dpc-4713	23	19	,	,	PUNCT
dpc-4713	23	20	and	and	CCONJ
dpc-4713	23	21	lamellar	lamellar	ADJ
dpc-4713	23	22	ichthyosis	ichthyosis	NOUN
dpc-4713	23	23	-	-	PUNCT
dpc-4713	23	24	like	like	ADJ
dpc-4713	23	25	.	.	PUNCT
dpc-4713	24	1	it	it	PRON
dpc-4713	24	2	was	be	AUX
dpc-4713	24	3	proposed	propose	VERB
dpc-4713	24	4	because	because	SCONJ
dpc-4713	24	5	,	,	PUNCT
dpc-4713	24	6	regardless	regardless	ADV
dpc-4713	24	7	of	of	ADP
dpc-4713	24	8	its	its	PRON
dpc-4713	24	9	extensive	extensive	ADJ
dpc-4713	24	10	total	total	ADJ
dpc-4713	24	11	body	body	NOUN
dpc-4713	24	12	surface	surface	NOUN
dpc-4713	24	13	area	area	NOUN
dpc-4713	24	14	involvement	involvement	NOUN
dpc-4713	24	15	,	,	PUNCT
dpc-4713	24	16	it	it	PRON
dpc-4713	24	17	is	be	AUX
dpc-4713	24	18	a	a	DET
dpc-4713	24	19	benign	benign	ADJ
dpc-4713	24	20	,	,	PUNCT
dpc-4713	24	21	temporary	temporary	ADJ
dpc-4713	24	22	condition	condition	NOUN
dpc-4713	24	23	that	that	PRON
dpc-4713	24	24	does	do	AUX
dpc-4713	24	25	not	not	PART
dpc-4713	24	26	require	require	VERB
dpc-4713	24	27	discontinuing	discontinue	VERB
dpc-4713	24	28	the	the	DET
dpc-4713	24	29	medication	medication	NOUN
dpc-4713	25	1	[	[	X
dpc-4713	25	2	5	5	NUM
dpc-4713	25	3	]	]	PUNCT
dpc-4713	25	4	.	.	PUNCT
dpc-4713	26	1	case	case	NOUN
dpc-4713	26	2	presentation	presentation	NOUN
dpc-4713	26	3	a	a	DET
dpc-4713	26	4	59	59	NUM
dpc-4713	26	5	-	-	PUNCT
dpc-4713	26	6	year	year	NOUN
dpc-4713	26	7	-	-	PUNCT
dpc-4713	26	8	old	old	ADJ
dpc-4713	26	9	woman	woman	NOUN
dpc-4713	26	10	was	be	AUX
dpc-4713	26	11	diagnosed	diagnose	VERB
dpc-4713	26	12	with	with	ADP
dpc-4713	26	13	ph+	ph+	NOUN
dpc-4713	26	14	all	all	ADV
dpc-4713	26	15	in	in	ADP
dpc-4713	26	16	2022	2022	NUM
dpc-4713	26	17	and	and	CCONJ
dpc-4713	26	18	began	begin	VERB
dpc-4713	26	19	treatment	treatment	NOUN
dpc-4713	26	20	with	with	ADP
dpc-4713	26	21	imatinib	imatinib	NOUN
dpc-4713	26	22	.	.	PUNCT
dpc-4713	27	1	upon	upon	SCONJ
dpc-4713	27	2	detecting	detect	VERB
dpc-4713	27	3	t315i	t315i	PROPN
dpc-4713	27	4	mutation	mutation	NOUN
dpc-4713	27	5	,	,	PUNCT
dpc-4713	27	6	the	the	DET
dpc-4713	27	7	treatment	treatment	NOUN
dpc-4713	27	8	was	be	AUX
dpc-4713	27	9	switched	switch	VERB
dpc-4713	27	10	to	to	ADP
dpc-4713	27	11	ponatinib	ponatinib	NOUN
dpc-4713	27	12	with	with	ADP
dpc-4713	27	13	a	a	DET
dpc-4713	27	14	daily	daily	ADJ
dpc-4713	27	15	dosage	dosage	NOUN
dpc-4713	27	16	of	of	ADP
dpc-4713	27	17	45	45	NUM
dpc-4713	27	18	mg	mg	NOUN
dpc-4713	27	19	.	.	PUNCT
dpc-4713	28	1	twenty	twenty	NUM
dpc-4713	28	2	-	-	PUNCT
dpc-4713	28	3	seven	seven	NUM
dpc-4713	28	4	days	day	NOUN
dpc-4713	28	5	after	after	ADP
dpc-4713	28	6	initiating	initiate	VERB
dpc-4713	28	7	ponatinib	ponatinib	NOUN
dpc-4713	28	8	,	,	PUNCT
dpc-4713	28	9	she	she	PRON
dpc-4713	28	10	developed	develop	VERB
dpc-4713	28	11	a	a	DET
dpc-4713	28	12	cadr	cadr	PROPN
dpc-4713	28	13	that	that	PRON
dpc-4713	28	14	affected	affect	VERB
dpc-4713	28	15	all	all	DET
dpc-4713	28	16	body	body	NOUN
dpc-4713	28	17	2	2	NUM
dpc-4713	28	18	research	research	NOUN
dpc-4713	28	19	letter	letter	NOUN
dpc-4713	29	1	|	|	ADV
dpc-4713	29	2	dermatol	dermatol	ADJ
dpc-4713	29	3	pract	pract	NOUN
dpc-4713	29	4	concept	concept	NOUN
dpc-4713	29	5	.	.	PUNCT
dpc-4713	30	1	2025;15(1):4713	2025;15(1):4713	NUM
dpc-4713	30	2	segments	segment	NOUN
dpc-4713	30	3	.	.	PUNCT
dpc-4713	31	1	the	the	DET
dpc-4713	31	2	lesions	lesion	NOUN
dpc-4713	31	3	were	be	AUX
dpc-4713	31	4	characterized	characterize	VERB
dpc-4713	31	5	by	by	ADP
dpc-4713	31	6	the	the	DET
dpc-4713	31	7	presence	presence	NOUN
dpc-4713	31	8	of	of	ADP
dpc-4713	31	9	plaques	plaque	NOUN
dpc-4713	31	10	with	with	ADP
dpc-4713	31	11	erythematous	erythematous	ADJ
dpc-4713	31	12	-	-	PUNCT
dpc-4713	31	13	purpuric	purpuric	ADJ
dpc-4713	31	14	and	and	CCONJ
dpc-4713	31	15	ochre	ochre	ADJ
dpc-4713	31	16	hues	hue	NOUN
dpc-4713	31	17	,	,	PUNCT
dpc-4713	31	18	arranged	arrange	VERB
dpc-4713	31	19	in	in	ADP
dpc-4713	31	20	a	a	DET
dpc-4713	31	21	reticular	reticular	ADJ
dpc-4713	31	22	pattern	pattern	NOUN
dpc-4713	31	23	with	with	ADP
dpc-4713	31	24	fine	fine	ADJ
dpc-4713	31	25	adherent	adherent	ADJ
dpc-4713	31	26	scaling	scaling	NOUN
dpc-4713	31	27	at	at	ADP
dpc-4713	31	28	the	the	DET
dpc-4713	31	29	center	center	NOUN
dpc-4713	31	30	,	,	PUNCT
dpc-4713	31	31	and	and	CCONJ
dpc-4713	31	32	surrounded	surround	VERB
dpc-4713	31	33	by	by	ADP
dpc-4713	31	34	a	a	DET
dpc-4713	31	35	halo	halo	NOUN
dpc-4713	31	36	of	of	ADP
dpc-4713	31	37	increased	increase	VERB
dpc-4713	31	38	erythema	erythema	NOUN
dpc-4713	31	39	.	.	PUNCT
dpc-4713	32	1	over	over	ADP
dpc-4713	32	2	time	time	NOUN
dpc-4713	32	3	,	,	PUNCT
dpc-4713	32	4	the	the	DET
dpc-4713	32	5	lesions	lesion	NOUN
dpc-4713	32	6	evolved	evolve	VERB
dpc-4713	32	7	with	with	ADP
dpc-4713	32	8	blood	blood	NOUN
dpc-4713	32	9	-	-	PUNCT
dpc-4713	32	10	tinged	tinge	VERB
dpc-4713	32	11	scaling	scaling	NOUN
dpc-4713	32	12	.	.	PUNCT
dpc-4713	33	1	no	no	DET
dpc-4713	33	2	involvement	involvement	NOUN
dpc-4713	33	3	of	of	ADP
dpc-4713	33	4	mucous	mucous	ADJ
dpc-4713	33	5	membranes	membrane	NOUN
dpc-4713	33	6	was	be	AUX
dpc-4713	33	7	observed	observe	VERB
dpc-4713	33	8	(	(	PUNCT
dpc-4713	33	9	figure	figure	NOUN
dpc-4713	33	10	1	1	NUM
dpc-4713	33	11	,	,	PUNCT
dpc-4713	33	12	a	a	DET
dpc-4713	33	13	-	-	PUNCT
dpc-4713	33	14	c	c	NOUN
dpc-4713	33	15	)	)	PUNCT
dpc-4713	33	16	.	.	PUNCT
dpc-4713	34	1	histopathologic	histopathologic	PROPN
dpc-4713	34	2	examination	examination	NOUN
dpc-4713	34	3	showed	show	VERB
dpc-4713	34	4	pauciinflammatory	pauciinflammatory	ADJ
dpc-4713	34	5	subepidermal	subepidermal	NOUN
dpc-4713	34	6	blistering	blister	VERB
dpc-4713	34	7	dermatosis	dermatosis	NOUN
dpc-4713	34	8	with	with	ADP
dpc-4713	34	9	multiple	multiple	ADJ
dpc-4713	34	10	necrotic	necrotic	ADJ
dpc-4713	34	11	keratinocytes	keratinocyte	NOUN
dpc-4713	34	12	and	and	CCONJ
dpc-4713	34	13	lymphocytic	lymphocytic	ADJ
dpc-4713	34	14	and	and	CCONJ
dpc-4713	34	15	neutrophilic	neutrophilic	ADJ
dpc-4713	34	16	infiltration	infiltration	NOUN
dpc-4713	34	17	(	(	PUNCT
dpc-4713	34	18	figure	figure	NOUN
dpc-4713	34	19	2	2	NUM
dpc-4713	34	20	,	,	PUNCT
dpc-4713	34	21	a	a	DET
dpc-4713	34	22	-	-	PUNCT
dpc-4713	34	23	d	d	NOUN
dpc-4713	34	24	)	)	PUNCT
dpc-4713	34	25	.	.	PUNCT
dpc-4713	35	1	although	although	SCONJ
dpc-4713	35	2	these	these	DET
dpc-4713	35	3	histological	histological	ADJ
dpc-4713	35	4	features	feature	NOUN
dpc-4713	35	5	were	be	AUX
dpc-4713	35	6	consistent	consistent	ADJ
dpc-4713	35	7	with	with	ADP
dpc-4713	35	8	findings	finding	NOUN
dpc-4713	35	9	described	describe	VERB
dpc-4713	35	10	in	in	ADP
dpc-4713	35	11	sjs	sjs	PROPN
dpc-4713	35	12	and	and	CCONJ
dpc-4713	35	13	other	other	ADJ
dpc-4713	35	14	cadr	cadr	PROPN
dpc-4713	35	15	,	,	PUNCT
dpc-4713	35	16	the	the	DET
dpc-4713	35	17	clinical	clinical	ADJ
dpc-4713	35	18	presentation	presentation	NOUN
dpc-4713	35	19	of	of	ADP
dpc-4713	35	20	our	our	PRON
dpc-4713	35	21	patient	patient	NOUN
dpc-4713	35	22	,	,	PUNCT
dpc-4713	35	23	including	include	VERB
dpc-4713	35	24	the	the	DET
dpc-4713	35	25	absence	absence	NOUN
dpc-4713	35	26	of	of	ADP
dpc-4713	35	27	other	other	ADJ
dpc-4713	35	28	clinical	clinical	ADJ
dpc-4713	35	29	features	feature	NOUN
dpc-4713	35	30	such	such	ADJ
dpc-4713	35	31	as	as	ADP
dpc-4713	35	32	mucosal	mucosal	NOUN
dpc-4713	35	33	involvement	involvement	NOUN
dpc-4713	35	34	,	,	PUNCT
dpc-4713	35	35	conjunctival	conjunctival	ADJ
dpc-4713	35	36	inflammation	inflammation	NOUN
dpc-4713	35	37	,	,	PUNCT
dpc-4713	35	38	and	and	CCONJ
dpc-4713	35	39	absence	absence	NOUN
dpc-4713	35	40	of	of	ADP
dpc-4713	35	41	blisters	blister	NOUN
dpc-4713	35	42	,	,	PUNCT
dpc-4713	35	43	or	or	CCONJ
dpc-4713	35	44	the	the	DET
dpc-4713	35	45	nikolsky	nikolsky	ADJ
dpc-4713	35	46	sign	sign	NOUN
dpc-4713	35	47	,	,	PUNCT
dpc-4713	35	48	led	lead	VERB
dpc-4713	35	49	us	we	PRON
dpc-4713	35	50	to	to	PART
dpc-4713	35	51	conclude	conclude	VERB
dpc-4713	35	52	that	that	SCONJ
dpc-4713	35	53	sjs	sjs	PROPN
dpc-4713	35	54	was	be	AUX
dpc-4713	35	55	an	an	DET
dpc-4713	35	56	unlikely	unlikely	ADJ
dpc-4713	35	57	diagnosis	diagnosis	NOUN
dpc-4713	35	58	.	.	PUNCT
dpc-4713	36	1	due	due	ADP
dpc-4713	36	2	to	to	ADP
dpc-4713	36	3	discrepancy	discrepancy	NOUN
dpc-4713	36	4	between	between	ADP
dpc-4713	36	5	clinical	clinical	ADJ
dpc-4713	36	6	figure	figure	NOUN
dpc-4713	36	7	1	1	NUM
dpc-4713	36	8	.	.	PUNCT
dpc-4713	37	1	(	(	PUNCT
dpc-4713	37	2	a	a	DET
dpc-4713	37	3	-	-	PUNCT
dpc-4713	37	4	c	c	NOUN
dpc-4713	37	5	)	)	PUNCT
dpc-4713	37	6	plaques	plaque	NOUN
dpc-4713	37	7	with	with	ADP
dpc-4713	37	8	erythematous	erythematous	ADJ
dpc-4713	37	9	purpuric	purpuric	ADJ
dpc-4713	37	10	and	and	CCONJ
dpc-4713	37	11	ochre	ochre	ADJ
dpc-4713	37	12	hues	hue	NOUN
dpc-4713	37	13	,	,	PUNCT
dpc-4713	37	14	arranged	arrange	VERB
dpc-4713	37	15	in	in	ADP
dpc-4713	37	16	a	a	DET
dpc-4713	37	17	reticular	reticular	ADJ
dpc-4713	37	18	pattern	pattern	NOUN
dpc-4713	37	19	and	and	CCONJ
dpc-4713	37	20	surrounded	surround	VERB
dpc-4713	37	21	by	by	ADP
dpc-4713	37	22	a	a	DET
dpc-4713	37	23	halo	halo	NOUN
dpc-4713	37	24	of	of	ADP
dpc-4713	37	25	increased	increase	VERB
dpc-4713	37	26	erythema	erythema	NOUN
dpc-4713	37	27	.	.	PUNCT
dpc-4713	38	1	in	in	ADP
dpc-4713	38	2	some	some	DET
dpc-4713	38	3	central	central	ADJ
dpc-4713	38	4	areas	area	NOUN
dpc-4713	38	5	of	of	ADP
dpc-4713	38	6	the	the	DET
dpc-4713	38	7	lesions	lesion	NOUN
dpc-4713	38	8	,	,	PUNCT
dpc-4713	38	9	there	there	PRON
dpc-4713	38	10	is	be	VERB
dpc-4713	38	11	evidence	evidence	NOUN
dpc-4713	38	12	of	of	ADP
dpc-4713	38	13	fine	fine	ADJ
dpc-4713	38	14	adherent	adherent	ADJ
dpc-4713	38	15	scaling	scaling	NOUN
dpc-4713	38	16	.	.	PUNCT
dpc-4713	39	1	(	(	PUNCT
dpc-4713	39	2	d	d	X
dpc-4713	39	3	)	)	PUNCT
dpc-4713	39	4	hypopigmented	hypopigmente	VERB
dpc-4713	39	5	post	post	ADJ
dpc-4713	39	6	-	-	ADJ
dpc-4713	39	7	inflammatory	inflammatory	ADJ
dpc-4713	39	8	patches	patch	NOUN
dpc-4713	39	9	with	with	ADP
dpc-4713	39	10	a	a	DET
dpc-4713	39	11	reticulated	reticulated	ADJ
dpc-4713	39	12	appearance	appearance	NOUN
dpc-4713	39	13	.	.	PUNCT
dpc-4713	40	1	figure	figure	NOUN
dpc-4713	40	2	2	2	NUM
dpc-4713	40	3	.	.	PUNCT
dpc-4713	41	1	(	(	PUNCT
dpc-4713	41	2	a	a	PRON
dpc-4713	41	3	,	,	PUNCT
dpc-4713	41	4	b	b	NOUN
dpc-4713	41	5	)	)	PUNCT
dpc-4713	41	6	skin	skin	NOUN
dpc-4713	41	7	biopsy	biopsy	NOUN
dpc-4713	41	8	of	of	ADP
dpc-4713	41	9	the	the	DET
dpc-4713	41	10	back	back	NOUN
dpc-4713	41	11	show	show	NOUN
dpc-4713	41	12	pauci	pauci	NOUN
dpc-4713	41	13	-	-	PUNCT
dpc-4713	41	14	inflammatory	inflammatory	ADJ
dpc-4713	41	15	subepidermal	subepidermal	NOUN
dpc-4713	41	16	blistering	blister	VERB
dpc-4713	41	17	dermatosis	dermatosis	NOUN
dpc-4713	41	18	with	with	ADP
dpc-4713	41	19	multiple	multiple	ADJ
dpc-4713	41	20	necrotic	necrotic	ADJ
dpc-4713	41	21	keratinocytes	keratinocyte	NOUN
dpc-4713	41	22	and	and	CCONJ
dpc-4713	41	23	lymphocytic	lymphocytic	ADJ
dpc-4713	41	24	and	and	CCONJ
dpc-4713	41	25	neutrophilic	neutrophilic	ADJ
dpc-4713	41	26	infiltration	infiltration	NOUN
dpc-4713	41	27	(	(	PUNCT
dpc-4713	41	28	h&e	h&e	PROPN
dpc-4713	41	29	,	,	PUNCT
dpc-4713	41	30	x4	x4	PROPN
dpc-4713	41	31	)	)	PUNCT
dpc-4713	41	32	.	.	PUNCT
dpc-4713	42	1	(	(	PUNCT
dpc-4713	42	2	c	c	X
dpc-4713	42	3	,	,	PUNCT
dpc-4713	42	4	d	d	NOUN
dpc-4713	42	5	)	)	PUNCT
dpc-4713	42	6	higher	high	ADJ
dpc-4713	42	7	magnification	magnification	NOUN
dpc-4713	42	8	(	(	PUNCT
dpc-4713	42	9	x40	x40	PROPN
dpc-4713	42	10	)	)	PUNCT
dpc-4713	42	11	.	.	PUNCT
dpc-4713	43	1	research	research	NOUN
dpc-4713	43	2	letter	letter	NOUN
dpc-4713	43	3	|	|	ADV
dpc-4713	43	4	dermatol	dermatol	ADJ
dpc-4713	43	5	pract	pract	NOUN
dpc-4713	43	6	concept	concept	NOUN
dpc-4713	43	7	.	.	PUNCT
dpc-4713	44	1	2025;15(1):4713	2025;15(1):4713	NUM
dpc-4713	44	2	3	3	NUM
dpc-4713	44	3	references	reference	NOUN
dpc-4713	44	4	1	1	NUM
dpc-4713	44	5	.	.	X
dpc-4713	45	1	ikeda	ikeda	PROPN
dpc-4713	45	2	m	m	PROPN
dpc-4713	45	3	,	,	PUNCT
dpc-4713	45	4	fujita	fujita	PROPN
dpc-4713	45	5	t	t	PROPN
dpc-4713	45	6	,	,	PUNCT
dpc-4713	45	7	amoh	amoh	PROPN
dpc-4713	45	8	y	y	PROPN
dpc-4713	45	9	,	,	PUNCT
dpc-4713	45	10	mii	mii	PROPN
dpc-4713	45	11	s	s	PROPN
dpc-4713	45	12	,	,	PUNCT
dpc-4713	45	13	matsumoto	matsumoto	PROPN
dpc-4713	45	14	k	k	PROPN
dpc-4713	45	15	,	,	PUNCT
dpc-4713	45	16	iwamura	iwamura	NOUN
dpc-4713	45	17	m.	m.	NOUN
dpc-4713	45	18	stevens	stevens	PROPN
dpc-4713	45	19	-	-	PUNCT
dpc-4713	45	20	johnson	johnson	PROPN
dpc-4713	45	21	syndrome	syndrome	NOUN
dpc-4713	45	22	induced	induce	VERB
dpc-4713	45	23	by	by	ADP
dpc-4713	45	24	sorafenib	sorafenib	NOUN
dpc-4713	45	25	for	for	ADP
dpc-4713	45	26	metastatic	metastatic	ADJ
dpc-4713	45	27	renal	renal	ADJ
dpc-4713	45	28	cell	cell	NOUN
dpc-4713	45	29	carcinoma	carcinoma	NOUN
dpc-4713	45	30	.	.	PUNCT
dpc-4713	46	1	urol	urol	PROPN
dpc-4713	46	2	int	int	PROPN
dpc-4713	46	3	.	.	PUNCT
dpc-4713	47	1	2013;91(4):482	2013;91(4):482	NUM
dpc-4713	47	2	-	-	SYM
dpc-4713	47	3	3	3	NUM
dpc-4713	47	4	.	.	PUNCT
dpc-4713	47	5	doi	doi	NOUN
dpc-4713	47	6	:	:	PUNCT
dpc-4713	47	7	10.1159	10.1159	NUM
dpc-4713	47	8	/000351918	/000351918	NOUN
dpc-4713	47	9	.	.	PUNCT
dpc-4713	48	1	pmid	pmid	NOUN
dpc-4713	48	2	:	:	PUNCT
dpc-4713	48	3	23969404	23969404	NUM
dpc-4713	48	4	.	.	PUNCT
dpc-4713	49	1	2	2	X
dpc-4713	49	2	.	.	X
dpc-4713	49	3	massaro	massaro	PROPN
dpc-4713	49	4	f	f	PROPN
dpc-4713	49	5	,	,	PUNCT
dpc-4713	49	6	molica	molica	PROPN
dpc-4713	49	7	m	m	PROPN
dpc-4713	49	8	,	,	PUNCT
dpc-4713	49	9	breccia	breccia	PROPN
dpc-4713	49	10	m.	m.	NOUN
dpc-4713	49	11	ponatinib	ponatinib	PROPN
dpc-4713	49	12	:	:	PUNCT
dpc-4713	49	13	a	a	DET
dpc-4713	49	14	review	review	NOUN
dpc-4713	49	15	of	of	ADP
dpc-4713	49	16	efficacy	efficacy	NOUN
dpc-4713	49	17	and	and	CCONJ
dpc-4713	49	18	safety	safety	NOUN
dpc-4713	49	19	.	.	PUNCT
dpc-4713	50	1	curr	curr	PROPN
dpc-4713	50	2	cancer	cancer	NOUN
dpc-4713	50	3	drug	drug	NOUN
dpc-4713	50	4	targets	target	NOUN
dpc-4713	50	5	.	.	PUNCT
dpc-4713	51	1	2018;18(9	2018;18(9	NUM
dpc-4713	51	2	):	):	PUNCT
dpc-4713	51	3	847	847	NUM
dpc-4713	51	4	-	-	SYM
dpc-4713	51	5	56	56	NUM
dpc-4713	51	6	.	.	PUNCT
dpc-4713	51	7	doi	doi	NOUN
dpc-4713	51	8	:	:	PUNCT
dpc-4713	51	9	10.2174/1568009617666171002142659	10.2174/1568009617666171002142659	NUM
dpc-4713	51	10	.	.	PUNCT
dpc-4713	52	1	pmid	pmid	NOUN
dpc-4713	52	2	:	:	PUNCT
dpc-4713	52	3	28969556	28969556	NUM
dpc-4713	52	4	.	.	PUNCT
dpc-4713	53	1	3	3	X
dpc-4713	53	2	.	.	X
dpc-4713	53	3	hsiao	hsiao	PROPN
dpc-4713	53	4	lt	lt	PROPN
dpc-4713	53	5	,	,	PUNCT
dpc-4713	53	6	chung	chung	PROPN
dpc-4713	53	7	hm	hm	PROPN
dpc-4713	53	8	,	,	PUNCT
dpc-4713	53	9	lin	lin	PROPN
dpc-4713	53	10	jt	jt	PROPN
dpc-4713	53	11	,	,	PUNCT
dpc-4713	53	12	et	et	PROPN
dpc-4713	53	13	al	al	PROPN
dpc-4713	53	14	.	.	PROPN
dpc-4713	53	15	stevens	stevens	PROPN
dpc-4713	53	16	-	-	PUNCT
dpc-4713	53	17	johnson	johnson	PROPN
dpc-4713	53	18	syndrome	syndrome	NOUN
dpc-4713	53	19	after	after	ADP
dpc-4713	53	20	treatment	treatment	NOUN
dpc-4713	53	21	with	with	ADP
dpc-4713	53	22	sti571	sti571	PROPN
dpc-4713	53	23	:	:	PUNCT
dpc-4713	53	24	a	a	DET
dpc-4713	53	25	case	case	NOUN
dpc-4713	53	26	report	report	NOUN
dpc-4713	53	27	.	.	PUNCT
dpc-4713	54	1	br	br	PROPN
dpc-4713	54	2	j	j	PROPN
dpc-4713	54	3	haematol	haematol	NOUN
dpc-4713	54	4	.	.	PUNCT
dpc-4713	55	1	2002;117(3):620	2002;117(3):620	NUM
dpc-4713	55	2	-	-	PUNCT
dpc-4713	55	3	22	22	NUM
dpc-4713	55	4	.	.	PUNCT
dpc-4713	56	1	doi:10.1046	doi:10.1046	ADJ
dpc-4713	56	2	/	/	SYM
dpc-4713	56	3	j.1365	j.1365	NOUN
dpc-4713	56	4	-	-	PUNCT
dpc-4713	56	5	2141.2002.03499.x	2141.2002.03499.x	NUM
dpc-4713	56	6	.	.	PUNCT
dpc-4713	57	1	pmid	pmid	NOUN
dpc-4713	57	2	:	:	PUNCT
dpc-4713	57	3	12028031	12028031	NUM
dpc-4713	57	4	.	.	PUNCT
dpc-4713	58	1	4	4	X
dpc-4713	58	2	.	.	X
dpc-4713	58	3	chaigne	chaigne	PROPN
dpc-4713	58	4	b	b	NOUN
dpc-4713	58	5	,	,	PUNCT
dpc-4713	58	6	lagier	lagier	PROPN
dpc-4713	58	7	l	l	PROPN
dpc-4713	58	8	,	,	PUNCT
dpc-4713	58	9	aubourg	aubourg	VERB
dpc-4713	58	10	a	a	DET
dpc-4713	58	11	,	,	PUNCT
dpc-4713	58	12	et	et	PROPN
dpc-4713	58	13	al	al	PROPN
dpc-4713	58	14	.	.	PROPN
dpc-4713	58	15	stevens	stevens	PROPN
dpc-4713	58	16	-	-	PUNCT
dpc-4713	58	17	johnson	johnson	PROPN
dpc-4713	58	18	syndrome	syndrome	NOUN
dpc-4713	58	19	induced	induce	VERB
dpc-4713	58	20	by	by	ADP
dpc-4713	58	21	masitinib	masitinib	NOUN
dpc-4713	58	22	.	.	PUNCT
dpc-4713	59	1	acta	acta	PROPN
dpc-4713	59	2	derm	derm	PROPN
dpc-4713	59	3	venereol	venereol	NOUN
dpc-4713	59	4	.	.	PUNCT
dpc-4713	60	1	2012;92(2):210	2012;92(2):210	NOUN
dpc-4713	60	2	-	-	PUNCT
dpc-4713	60	3	2	2	NUM
dpc-4713	60	4	.	.	PUNCT
dpc-4713	60	5	doi	doi	NOUN
dpc-4713	60	6	:	:	PUNCT
dpc-4713	60	7	10.2340/00015555	10.2340/00015555	NUM
dpc-4713	60	8	-	-	SYM
dpc-4713	60	9	1196	1196	NUM
dpc-4713	60	10	.	.	PUNCT
dpc-4713	61	1	pmid	pmid	NOUN
dpc-4713	61	2	:	:	PUNCT
dpc-4713	61	3	21953477	21953477	NUM
dpc-4713	61	4	.	.	PUNCT
dpc-4713	62	1	5	5	X
dpc-4713	62	2	.	.	X
dpc-4713	62	3	danish	danish	PROPN
dpc-4713	62	4	m	m	PROPN
dpc-4713	62	5	,	,	PUNCT
dpc-4713	62	6	patel	patel	PROPN
dpc-4713	62	7	v	v	PROPN
dpc-4713	62	8	,	,	PUNCT
dpc-4713	62	9	arava	arava	PROPN
dpc-4713	62	10	s	s	PROPN
dpc-4713	62	11	,	,	PUNCT
dpc-4713	62	12	ahuja	ahuja	PROPN
dpc-4713	62	13	r.	r.	PROPN
dpc-4713	62	14	ponatinib	ponatinib	PROPN
dpc-4713	62	15	-	-	PUNCT
dpc-4713	62	16	induced	induce	VERB
dpc-4713	62	17	desquamation	desquamation	NOUN
dpc-4713	62	18	-	-	PUNCT
dpc-4713	62	19	unifying	unify	VERB
dpc-4713	62	20	eponymous	eponymous	ADJ
dpc-4713	62	21	terminology	terminology	NOUN
dpc-4713	62	22	for	for	ADP
dpc-4713	62	23	a	a	DET
dpc-4713	62	24	rare	rare	ADJ
dpc-4713	62	25	adverse	adverse	ADJ
dpc-4713	62	26	event	event	NOUN
dpc-4713	62	27	.	.	PUNCT
dpc-4713	63	1	j	j	PROPN
dpc-4713	63	2	eur	eur	PROPN
dpc-4713	63	3	acad	acad	PROPN
dpc-4713	63	4	dermatol	dermatol	NOUN
dpc-4713	63	5	venereol	venereol	NOUN
dpc-4713	63	6	.	.	PUNCT
dpc-4713	64	1	2024;38(3	2024;38(3	NUM
dpc-4713	64	2	):	):	PUNCT
dpc-4713	64	3	e247	e247	PROPN
dpc-4713	64	4	-	-	PUNCT
dpc-4713	64	5	e249	e249	PROPN
dpc-4713	64	6	.	.	PUNCT
dpc-4713	65	1	doi:10.1111	doi:10.1111	PROPN
dpc-4713	65	2	/	/	SYM
dpc-4713	65	3	jdv.19553	jdv.19553	PROPN
dpc-4713	65	4	.	.	PUNCT
dpc-4713	65	5	pmid	pmid	NOUN
dpc-4713	65	6	:	:	PUNCT
dpc-4713	65	7	37795667	37795667	NUM
dpc-4713	65	8	.	.	PUNCT
dpc-4713	66	1	and	and	CCONJ
dpc-4713	66	2	pathological	pathological	ADJ
dpc-4713	66	3	findings	finding	NOUN
dpc-4713	66	4	and	and	CCONJ
dpc-4713	66	5	the	the	DET
dpc-4713	66	6	persistent	persistent	ADJ
dpc-4713	66	7	cytopenias	cytopenia	NOUN
dpc-4713	66	8	,	,	PUNCT
dpc-4713	66	9	it	it	PRON
dpc-4713	66	10	was	be	AUX
dpc-4713	66	11	decided	decide	VERB
dpc-4713	66	12	to	to	PART
dpc-4713	66	13	discontinue	discontinue	VERB
dpc-4713	66	14	ponatinib	ponatinib	NOUN
dpc-4713	66	15	treatment	treatment	NOUN
dpc-4713	66	16	.	.	PUNCT
dpc-4713	67	1	resolution	resolution	NOUN
dpc-4713	67	2	of	of	ADP
dpc-4713	67	3	the	the	DET
dpc-4713	67	4	initial	initial	ADJ
dpc-4713	67	5	lesions	lesion	NOUN
dpc-4713	67	6	resulted	result	VERB
dpc-4713	67	7	in	in	ADP
dpc-4713	67	8	post	post	ADJ
dpc-4713	67	9	-	-	ADJ
dpc-4713	67	10	inflammatory	inflammatory	ADJ
dpc-4713	67	11	hypopigmentation	hypopigmentation	NOUN
dpc-4713	67	12	(	(	PUNCT
dpc-4713	67	13	figure	figure	NOUN
dpc-4713	67	14	1d	1d	NUM
dpc-4713	67	15	)	)	PUNCT
dpc-4713	67	16	.	.	PUNCT
dpc-4713	68	1	conclusions	conclusion	NOUN
dpc-4713	68	2	we	we	PRON
dpc-4713	68	3	report	report	VERB
dpc-4713	68	4	a	a	DET
dpc-4713	68	5	cutaneous	cutaneous	ADJ
dpc-4713	68	6	reaction	reaction	NOUN
dpc-4713	68	7	with	with	ADP
dpc-4713	68	8	an	an	DET
dpc-4713	68	9	uncommon	uncommon	ADJ
dpc-4713	68	10	morphology	morphology	NOUN
dpc-4713	68	11	currently	currently	ADV
dpc-4713	68	12	known	know	VERB
dpc-4713	68	13	as	as	ADP
dpc-4713	68	14	ponatinib	ponatinib	ADV
dpc-4713	68	15	-	-	PUNCT
dpc-4713	68	16	induced	induce	VERB
dpc-4713	68	17	desquamation	desquamation	NOUN
dpc-4713	68	18	.	.	PUNCT
dpc-4713	69	1	our	our	PRON
dpc-4713	69	2	patient	patient	NOUN
dpc-4713	69	3	exhibited	exhibit	VERB
dpc-4713	69	4	skin	skin	NOUN
dpc-4713	69	5	lesions	lesion	NOUN
dpc-4713	69	6	with	with	ADP
dpc-4713	69	7	a	a	DET
dpc-4713	69	8	reticular	reticular	ADJ
dpc-4713	69	9	pattern	pattern	NOUN
dpc-4713	69	10	and	and	CCONJ
dpc-4713	69	11	peripheral	peripheral	ADJ
dpc-4713	69	12	erythema	erythema	NOUN
dpc-4713	69	13	,	,	PUNCT
dpc-4713	69	14	even	even	ADV
dpc-4713	69	15	though	though	SCONJ
dpc-4713	69	16	the	the	DET
dpc-4713	69	17	histopathological	histopathological	ADJ
dpc-4713	69	18	findings	finding	NOUN
dpc-4713	69	19	were	be	AUX
dpc-4713	69	20	consistent	consistent	ADJ
dpc-4713	69	21	with	with	ADP
dpc-4713	69	22	sjs	sjs	PROPN
dpc-4713	69	23	.	.	PUNCT
dpc-4713	70	1	we	we	PRON
dpc-4713	70	2	reported	report	VERB
dpc-4713	70	3	this	this	DET
dpc-4713	70	4	case	case	NOUN
dpc-4713	70	5	to	to	PART
dpc-4713	70	6	highlight	highlight	VERB
dpc-4713	70	7	the	the	DET
dpc-4713	70	8	significance	significance	NOUN
dpc-4713	70	9	of	of	ADP
dpc-4713	70	10	recording	record	VERB
dpc-4713	70	11	emerging	emerge	VERB
dpc-4713	70	12	cutaneous	cutaneous	ADJ
dpc-4713	70	13	reactions	reaction	NOUN
dpc-4713	70	14	linked	link	VERB
dpc-4713	70	15	to	to	ADP
dpc-4713	70	16	molecular	molecular	ADJ
dpc-4713	70	17	therapies	therapy	NOUN
dpc-4713	70	18	,	,	PUNCT
dpc-4713	70	19	emphasizing	emphasize	VERB
dpc-4713	70	20	the	the	DET
dpc-4713	70	21	importance	importance	NOUN
dpc-4713	70	22	of	of	ADP
dpc-4713	70	23	acting	act	VERB
dpc-4713	70	24	according	accord	VERB
dpc-4713	70	25	to	to	ADP
dpc-4713	70	26	evolution	evolution	NOUN
dpc-4713	70	27	in	in	ADP
dpc-4713	70	28	a	a	DET
dpc-4713	70	29	patient	patient	NOUN
dpc-4713	70	30	instead	instead	ADV
dpc-4713	70	31	of	of	ADP
dpc-4713	70	32	guiding	guide	VERB
dpc-4713	70	33	our	our	PRON
dpc-4713	70	34	treatment	treatment	NOUN
dpc-4713	70	35	based	base	VERB
dpc-4713	70	36	on	on	ADP
dpc-4713	70	37	only	only	ADV
dpc-4713	70	38	clinical	clinical	ADJ
dpc-4713	70	39	or	or	CCONJ
dpc-4713	70	40	histopathological	histopathological	ADJ
dpc-4713	70	41	findings	finding	NOUN
dpc-4713	70	42	,	,	PUNCT
dpc-4713	70	43	especially	especially	ADV
dpc-4713	70	44	when	when	SCONJ
dpc-4713	70	45	considering	consider	VERB
dpc-4713	70	46	the	the	DET
dpc-4713	70	47	implications	implication	NOUN
dpc-4713	70	48	for	for	ADP
dpc-4713	70	49	the	the	DET
dpc-4713	70	50	patient	patient	NOUN
dpc-4713	70	51	’s	’s	PART
dpc-4713	70	52	prognosis	prognosis	NOUN
dpc-4713	70	53	.	.	PUNCT